BRPI0417513A - agentes combinados de chp-gemcitabina e seu uso como substáncias antitumorais ativas - Google Patents

agentes combinados de chp-gemcitabina e seu uso como substáncias antitumorais ativas

Info

Publication number
BRPI0417513A
BRPI0417513A BRPI0417513-1A BRPI0417513A BRPI0417513A BR PI0417513 A BRPI0417513 A BR PI0417513A BR PI0417513 A BRPI0417513 A BR PI0417513A BR PI0417513 A BRPI0417513 A BR PI0417513A
Authority
BR
Brazil
Prior art keywords
chp
combined agents
antitumor substances
gemcitabine
active antitumor
Prior art date
Application number
BRPI0417513-1A
Other languages
English (en)
Inventor
Dagmar Braun
Original Assignee
Zoser B Salama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoser B Salama filed Critical Zoser B Salama
Publication of BRPI0417513A publication Critical patent/BRPI0417513A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"AGENTES COMBINADOS DE CHP-GEMCITABINA E SEU USO COMO SUBSTáNCIAS ANTITUMORAIS ATIVAS". A invenção se refere a agentes combinados, compreendendo cis hidroxiprolina (CHP) e gemcitabina, além do uso dos ditos agentes na profilaxia e terapia de tumores.
BRPI0417513-1A 2003-12-12 2004-12-13 agentes combinados de chp-gemcitabina e seu uso como substáncias antitumorais ativas BRPI0417513A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10359828A DE10359828A1 (de) 2003-12-12 2003-12-12 CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
PCT/DE2004/002760 WO2005056005A1 (de) 2003-12-12 2004-12-13 Chp-gemcitabin-kombinationsmittel und ihre verwendung als antitumorwirkstoffe

Publications (1)

Publication Number Publication Date
BRPI0417513A true BRPI0417513A (pt) 2007-03-06

Family

ID=34672934

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417513-1A BRPI0417513A (pt) 2003-12-12 2004-12-13 agentes combinados de chp-gemcitabina e seu uso como substáncias antitumorais ativas

Country Status (12)

Country Link
US (1) US20070207980A1 (pt)
EP (1) EP1701719A1 (pt)
JP (1) JP2007513894A (pt)
CN (1) CN1889946A (pt)
AU (1) AU2004296129A1 (pt)
BR (1) BRPI0417513A (pt)
CA (1) CA2548605A1 (pt)
DE (1) DE10359828A1 (pt)
MX (1) MXPA06006717A (pt)
RU (1) RU2006125081A (pt)
WO (1) WO2005056005A1 (pt)
ZA (1) ZA200605707B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120495A1 (en) * 2004-06-14 2005-12-22 Salama Zoser B Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
HRP20160625T1 (hr) 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
CN113413393B (zh) * 2013-08-19 2025-03-04 塔里斯生物医药公司 多单元药物递送装置和方法
CN105030682B (zh) * 2015-06-24 2018-02-09 广州复大医疗股份有限公司 一种纳米微粒胶体及其制备方法与用途
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153643A (en) * 1984-11-05 2000-11-28 Hoerrmann; Wilhelm Anti-cancer-substance
CA1281288C (en) * 1984-11-05 1991-03-12 Wilhelm Hoerrmann Tumor therapy
ES2152664T3 (es) * 1996-03-11 2001-02-01 Hoerrmann Wilhelm Combinacion de cis-4-hidroxi-l-prolina y n-metil-cis-4-hidroxi-l-prolina para aplicacion como agente terapeutico, especialmente para el tratamiento contra el cancer.
WO2001034134A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
EP1258248A3 (en) * 2001-05-18 2003-06-04 TAP Pharmaceutical Products, Inc. Tumor treatments comprising a fumagillol derivative and a further antineoplastic agent

Also Published As

Publication number Publication date
WO2005056005A1 (de) 2005-06-23
CN1889946A (zh) 2007-01-03
CA2548605A1 (en) 2005-06-23
ZA200605707B (en) 2008-02-27
MXPA06006717A (es) 2007-05-04
US20070207980A1 (en) 2007-09-06
JP2007513894A (ja) 2007-05-31
RU2006125081A (ru) 2008-01-20
EP1701719A1 (de) 2006-09-20
AU2004296129A2 (en) 2005-06-23
DE10359828A1 (de) 2005-07-28
AU2004296129A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
BR9916833A (pt) Derivados de epotilona e seu uso como agentes antitumor
TR201900764T4 (tr) LAG-3 ve terapötik antikorlar içeren bileşimler ve bunların kanser tedavisinde kullanımı.
RU2011115406A (ru) Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера
DOP2006000179A (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimiento de fabricación y utilización
MEP36208A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
ITMI20052171A1 (it) Composti e-amminocarbonil bicicloepten pirimidindiamminici stereoisomericamente arricchiti e loro uso
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
HRPK20041072B3 (hr) Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
CR9300A (es) Uso de compuestos de hierro (iii)
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
ATE245655T1 (de) Organische-arsenverbindungen
WO2003106384A3 (en) Novel boronic chalcone derivatives and uses thereof
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
UY28313A1 (es) Nonadepsipeptidos acilados
BRPI0417513A (pt) agentes combinados de chp-gemcitabina e seu uso como substáncias antitumorais ativas
MX2007004025A (es) Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._.
UY30629A1 (es) Nuevo péptido de actinomadura namibiensis
DE60323529D1 (de) Rutheniumkomplexe mit antikrebswirkung
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
PA8506201A1 (es) Quimioterapia de combinacion (combination chemotherapy)
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.